iShares Biotechnology ETF $IBB Shares Acquired by Point Nemo Capital LLC

Point Nemo Capital LLC lifted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 868.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,353 shares of the financial services provider’s stock after purchasing an additional 44,256 shares during the period. iShares Biotechnology ETF accounts for about 4.8% of Point Nemo Capital LLC’s portfolio, making the stock its largest holding. Point Nemo Capital LLC’s holdings in iShares Biotechnology ETF were worth $10,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in IBB. Endowment Wealth Management Inc. increased its holdings in shares of iShares Biotechnology ETF by 10.2% in the third quarter. Endowment Wealth Management Inc. now owns 6,273 shares of the financial services provider’s stock valued at $1,321,000 after purchasing an additional 582 shares during the last quarter. StoneX Group Inc. lifted its position in iShares Biotechnology ETF by 100.7% during the third quarter. StoneX Group Inc. now owns 2,688 shares of the financial services provider’s stock worth $557,000 after buying an additional 1,349 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in iShares Biotechnology ETF by 8.2% during the third quarter. Pictet Asset Management Holding SA now owns 59,475 shares of the financial services provider’s stock worth $12,552,000 after buying an additional 4,525 shares in the last quarter. Parallel Advisors LLC lifted its position in iShares Biotechnology ETF by 225.8% during the third quarter. Parallel Advisors LLC now owns 3,160 shares of the financial services provider’s stock worth $665,000 after buying an additional 2,190 shares in the last quarter. Finally, Flagship Wealth Advisors LLC boosted its stake in iShares Biotechnology ETF by 460.0% during the third quarter. Flagship Wealth Advisors LLC now owns 168 shares of the financial services provider’s stock worth $35,000 after buying an additional 138 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $213.63 on Friday. The stock’s fifty day moving average is $208.46 and its two-hundred day moving average is $185.91. iShares Biotechnology ETF has a fifty-two week low of $154.98 and a fifty-two week high of $222.29.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 annualized dividend and a dividend yield of 0.0%. This is a drop from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.